Letrozole in combination with trastuzumab is superior to letrozole monotherapy as first line treatment in patients with hormone-receptor-positive, HER2-positive metastatic breast cancer (MBC) – results of the eLEcTRA trial. - Huober,J.; Fasching,P.; Paepke,S. (Cancer Res, 2009)